vs
ACACIA RESEARCH CORP（ACTG）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
ACACIA RESEARCH CORP的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.5倍（$50.1M vs $33.4M），ACACIA RESEARCH CORP同比增速更快（2.6% vs -23.8%），过去两年ACACIA RESEARCH CORP的营收复合增速更高（43.6% vs -6.2%）
槐亚研究公司是一家总部位于纽约市的美国上市企业，在科技、能源以及工业制造领域开展业务收购与运营工作。该公司与控股股东斯塔博德价值投资合伙企业保持战略伙伴关系，这家企业在业内常被归类为专利流氓。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
ACTG vs DNA — 直观对比
营收规模更大
ACTG
是对方的1.5倍
$33.4M
营收增速更快
ACTG
高出26.5%
-23.8%
两年增速更快
ACTG
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.1M | $33.4M |
| 净利润 | $3.4M | — |
| 毛利率 | 12.8% | — |
| 营业利润率 | -26.1% | -211.9% |
| 净利率 | 6.8% | — |
| 营收同比 | 2.6% | -23.8% |
| 净利润同比 | 125.5% | — |
| 每股收益（稀释后） | $0.03 | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTGDNA
| Q4 25 | $50.1M | $33.4M | ||
| Q3 25 | $59.4M | $38.8M | ||
| Q2 25 | $51.2M | $49.6M | ||
| Q1 25 | $124.4M | $48.3M | ||
| Q4 24 | $48.8M | $43.8M | ||
| Q3 24 | $23.3M | $89.0M | ||
| Q2 24 | $25.8M | $56.2M | ||
| Q1 24 | $24.3M | $37.9M |
净利润ACTGDNA
| Q4 25 | $3.4M | — | ||
| Q3 25 | $-2.7M | $-80.8M | ||
| Q2 25 | $-3.3M | $-60.3M | ||
| Q1 25 | $24.3M | $-91.0M | ||
| Q4 24 | $-13.4M | — | ||
| Q3 24 | $-14.0M | $-56.4M | ||
| Q2 24 | $-8.4M | $-217.2M | ||
| Q1 24 | $-186.0K | $-165.9M |
毛利率ACTGDNA
| Q4 25 | 12.8% | — | ||
| Q3 25 | 21.2% | — | ||
| Q2 25 | 12.8% | — | ||
| Q1 25 | 47.4% | — | ||
| Q4 24 | 17.6% | — | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 26.2% | — | ||
| Q1 24 | 49.2% | — |
营业利润率ACTGDNA
| Q4 25 | -26.1% | -211.9% | ||
| Q3 25 | -10.8% | -231.8% | ||
| Q2 25 | -24.2% | -132.1% | ||
| Q1 25 | 30.8% | -184.1% | ||
| Q4 24 | -32.4% | -236.3% | ||
| Q3 24 | -44.1% | -62.0% | ||
| Q2 24 | -18.4% | -396.7% | ||
| Q1 24 | -8.6% | -469.1% |
净利率ACTGDNA
| Q4 25 | 6.8% | — | ||
| Q3 25 | -4.6% | -207.9% | ||
| Q2 25 | -6.4% | -121.6% | ||
| Q1 25 | 19.5% | -188.2% | ||
| Q4 24 | -27.5% | — | ||
| Q3 24 | -60.0% | -63.3% | ||
| Q2 24 | -32.7% | -386.4% | ||
| Q1 24 | -0.8% | -437.3% |
每股收益（稀释后）ACTGDNA
| Q4 25 | $0.03 | $-1.41 | ||
| Q3 25 | $-0.03 | $-1.45 | ||
| Q2 25 | $-0.03 | $-1.10 | ||
| Q1 25 | $0.25 | $-1.68 | ||
| Q4 24 | $-0.14 | $-1.91 | ||
| Q3 24 | $-0.14 | $-1.08 | ||
| Q2 24 | $-0.08 | $-4.23 | ||
| Q1 24 | $0.00 | $-3.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.7M | $422.6M |
| 总债务越低越好 | $91.9M | — |
| 股东权益账面价值 | $543.5M | $508.6M |
| 总资产 | $771.0M | $1.1B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTGDNA
| Q4 25 | $306.7M | $422.6M | ||
| Q3 25 | $301.8M | $495.5M | ||
| Q2 25 | $316.7M | $559.4M | ||
| Q1 25 | $272.0M | $325.3M | ||
| Q4 24 | $273.9M | $561.6M | ||
| Q3 24 | $410.9M | $616.2M | ||
| Q2 24 | $441.9M | $730.4M | ||
| Q1 24 | $498.4M | $840.4M |
总债务ACTGDNA
| Q4 25 | $91.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACTGDNA
| Q4 25 | $543.5M | $508.6M | ||
| Q3 25 | $537.6M | $559.8M | ||
| Q2 25 | $538.6M | $613.0M | ||
| Q1 25 | $540.2M | $647.4M | ||
| Q4 24 | $514.8M | $716.1M | ||
| Q3 24 | $540.2M | $797.9M | ||
| Q2 24 | $560.7M | $833.1M | ||
| Q1 24 | $568.3M | $987.3M |
总资产ACTGDNA
| Q4 25 | $771.0M | $1.1B | ||
| Q3 25 | $768.9M | $1.2B | ||
| Q2 25 | $775.5M | $1.2B | ||
| Q1 25 | $801.6M | $1.3B | ||
| Q4 24 | $756.4M | $1.4B | ||
| Q3 24 | $707.6M | $1.5B | ||
| Q2 24 | $753.6M | $1.6B | ||
| Q1 24 | $631.7M | $1.6B |
负债/权益比ACTGDNA
| Q4 25 | 0.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.2M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.7M |
| 自由现金流率自由现金流/营收 | — | -142.8% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 22.01× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACTGDNA
| Q4 25 | $75.2M | $-47.7M | ||
| Q3 25 | $9.5M | $-31.6M | ||
| Q2 25 | $50.1M | $-40.3M | ||
| Q1 25 | $2.4M | $-51.5M | ||
| Q4 24 | $50.1M | $-42.4M | ||
| Q3 24 | $-593.0K | $-103.5M | ||
| Q2 24 | $16.1M | $-84.4M | ||
| Q1 24 | $54.8M | $-89.3M |
自由现金流ACTGDNA
| Q4 25 | — | $-47.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-40.3M | ||
| Q1 25 | $335.0K | $-59.1M | ||
| Q4 24 | $-98.5M | $-56.1M | ||
| Q3 24 | $-2.8M | $-118.6M | ||
| Q2 24 | $-126.7M | $-111.4M | ||
| Q1 24 | $54.6M | $-96.0M |
自由现金流率ACTGDNA
| Q4 25 | — | -142.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -81.2% | ||
| Q1 25 | 0.3% | -122.4% | ||
| Q4 24 | -201.8% | -128.0% | ||
| Q3 24 | -12.1% | -133.2% | ||
| Q2 24 | -490.5% | -198.2% | ||
| Q1 24 | 224.4% | -252.9% |
资本支出强度ACTGDNA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | 1.7% | 15.8% | ||
| Q4 24 | 304.4% | 31.3% | ||
| Q3 24 | 9.6% | 16.9% | ||
| Q2 24 | 553.0% | 48.1% | ||
| Q1 24 | 1.1% | 17.7% |
现金转化率ACTGDNA
| Q4 25 | 22.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.10× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACTG
| Energy Operations | $16.0M | 32% |
| Transportation Safety | $10.4M | 21% |
| Office Storage And Display Solutions | $8.4M | 17% |
| Printers Consumables And Parts | $6.5M | 13% |
| Natural Gas Reserves | $5.1M | 10% |
| Natural Gas Liquids Reserves | $3.3M | 7% |
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
